Imbio PHA (4.0.0) vs ZEUS System
AI Verdict
Choose Imbio PHA (4.0.0) if…
Choose Imbio PHA if your clinical workflow involves CT pulmonary angiogram (CTPA) scans and you need rapid, automated assessment of cardiac structures to evaluate for right ventricular dilation. This tool is ideal for aiding in the diagnosis and risk stratification of conditions like pulmonary embolism and hypertension by providing objective measurements and ratios.
View Imbio PHA (4.0.0) →Choose ZEUS System if…
Choose the ZEUS System if you require long-term, continuous ECG monitoring for patients suspected of or diagnosed with cardiac arrhythmias, such as Atrial Fibrillation. This AI-powered solution is best suited for ambulatory patients needing extended data collection (up to 14 days) from wearable biosensors to detect and characterize intermittent or asymptomatic cardiac events.
View ZEUS System →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Imbio PHA (4.0.0) | ZEUS System |
|---|---|---|
| Pricing | Unknown | Not disclosed |
| Deployment | Cloud (AWS) or On-premise (VMware) or via partners (Nuance, Aidoc, Siemens Syngo.via, TeraRecon, FerrumHealth, Flywheel). | Cloud-based (AWS EC2 platform), no on-premise hardware. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Yes AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Imbio PHA (4.0.0)Imbio PHA emphasizes fully automated processing and seamless integration into existing radiology PACS and DICOM workflows, generating results without adding steps for the radiologist. This focus on minimal user intervention within established clinical imaging workflows suggests a high degree of usability. ZEUS System, while user-friendly for remote monitoring, still involves patient interaction with a wearable and data return.
Clinical Value
TieBoth tools are FDA-cleared and provide significant clinical value in their specialized areas. Imbio PHA offers automated, quantitative analysis from CT scans for acute conditions like pulmonary embolism, aiding in risk stratification. ZEUS System provides AI-powered continuous ECG monitoring for long-term arrhythmia detection and characterization, with high sensitivity and specificity for AFib.
Pricing & Value
TieNeither Imbio PHA nor ZEUS System provides transparent pricing information in the provided facts or through web searches. Both require direct contact for pricing details, making it impossible to compare their value proposition based on cost.
Enterprise Readiness
Imbio PHA (4.0.0)Imbio PHA offers greater deployment flexibility with options for cloud, enterprise (on-premise), or partner integration, which can be critical for large enterprises with varying infrastructure and data residency needs. While ZEUS System is cloud-based with EHR integration, its lack of an on-premise option might limit its appeal to some larger healthcare systems.
Innovation
ZEUS SystemThe ZEUS System demonstrates a slightly higher degree of innovation by integrating AI with wearable biosensors for long-term, continuous cardiac monitoring and early arrhythmia detection, particularly for Atrial Fibrillation. This approach leverages a large repository of labeled ECG data and addresses a growing need for proactive, non-invasive cardiac care.
Support & Docs
TieBoth Imbio PHA and ZEUS System provide readily accessible support and documentation. Imbio offers user manuals and an email for support, while iRhythm provides comprehensive instructions for use, clinical reference manuals, and customer care contact details including phone and email.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Imbio PHA (4.0.0) | ZEUS System |
|---|---|---|
| Name | Imbio PHA (4.0.0) | ZEUS System |
| Company | Imbio | iRhythm Technologies |
| Description | Imbio PHA (4.0.0) is an FDA-cleared AI-powered medical image processing software that automatically measures cardiac structures from CT pulmonary angiogram (CTPA) scans to assess potential right ventricular dilation and aid in the diagnosis and risk stratification of pulmonary embolism and hypertension. | The ZEUS System by iRhythm Technologies is an AI-powered software that analyzes ECG data from wearable biosensors for long-term continuous cardiac monitoring, aiding in the detection and characterization of arrhythmias like Atrial Fibrillation. |
| Categories | Cardiology AI, Radiology & Imaging AI | Cardiology AI, Wearables & Remote Monitoring (RPM) |
| Specialties | Cardiology, Pulmonology, Radiology | Cardiology, Family Medicine, Internal Medicine |
| Key Features | Automated measurement of right and left ventricle diameters, Automated measurement of main pulmonary artery and aorta diameters, Calculates RV/LV and PA/Ao ratios, Utilizes artificial intelligence algorithms for anatomical identification and measurement, Generates annotated DICOM images, Provides summary reports in PDF format, Integrates with native DICOM tools and workflows, Rapid, fully-automated assessment (typically in minutes) | AI-powered arrhythmia detection, Continuous ECG monitoring (up to 14 days), Cloud-based data analytics, Detection and characterization of Atrial Fibrillation (AFib), Preliminary report generation for physicians, Integration with Zio Watch and Zio monitors, Support for symptomatic and asymptomatic cardiac events, HL7-based EHR integration |
Videos
Demos, reviews, and walkthroughs featuring Imbio PHA (4.0.0) and ZEUS System.
Frequently Asked Questions
More Comparisons
More matchups featuring Imbio PHA (4.0.0) or ZEUS System
Backers
Who funded each tool's parent company.